Crohn's disease trials recruiting in Maryland

All Crohn's disease trials nationally

Cities in Maryland

Recruiting trials in Maryland

• A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
  NCT06764615 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Maryland: Glen Burnie
• A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
  NCT07499232 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Glen Burnie
• A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
  NCT07196722 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Chevy Chase, Glen Burnie
• A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
  NCT06581328 · Phase: Phase 4 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Maryland: Chevy Chase, Glen Burnie
• A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
  NCT05442567 · Phase: Phase 3 · Ages: 2 Years and older · Sex: All (male and female) · Maryland: Baltimore
• A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
  NCT04779320 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · Maryland: Baltimore
• A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
  NCT06233461 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Maryland: Glen Burnie
• A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
  NCT06819891 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female) · Maryland: Baltimore, Chevy Chase
• A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
  NCT06430801 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female) · Maryland: Bethesda
• An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
  NCT07184931 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female) · Maryland: Greenbelt
• An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab
  NCT03167437 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Maryland: Bethesda
• Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
  NCT05781152 · Phase: Phase 4 · Ages: 6 Years to 17 Years · Sex: All (male and female) · Maryland: Baltimore
• Immune Regulation in Ulcerative Colitis or Crohn s Disease
  NCT00001184 · Phase: Not specified · Ages: 1 Day to 75 Years · Sex: All (male and female) · Maryland: Bethesda
• Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
  NCT06937099 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Maryland: Chevy Chase
• Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
  NCT06548542 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Maryland: Chevy Chase, Rockville
• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
  NCT03816345 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore, Bethesda
• Zymfentra (Infliximab-dyyb) REal World Cohort STudy
  NCT07237516 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore